Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.

Takata T, Miyazaki M, Futo M, Hara S, Shiotsuka S, Kamimura H, Yoshimura H, Matsunaga A, Nishida T, Ishikura H, Ishikawa T, Tamura K, Tsuji BT.

Scand J Infect Dis. 2013 Mar;45(3):203-12. doi: 10.3109/00365548.2012.723221. Epub 2012 Oct 31.

PMID:
23113753
2.

Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.

Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.

J Antimicrob Chemother. 2011 Jul;66(7):1594-9. doi: 10.1093/jac/dkr169. Epub 2011 Apr 26.

PMID:
21525024
3.

Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.

Hanaki H, Cui L, Ikeda-Dantsuji Y, Nakae T, Honda J, Yanagihara K, Takesue Y, Matsumoto T, Sunakawa K, Kaku M, Tomono K, Fukuchi K, Kusachi S, Mikamo H, Takata T, Otsuka Y, Nagura O, Fujitani S, Aoki Y, Yamaguchi Y, Tateda K, Kadota J, Kohno S, Niki Y.

J Infect Chemother. 2014 Sep;20(9):527-34. doi: 10.1016/j.jiac.2014.06.012. Epub 2014 Jul 22.

PMID:
25066429
4.

Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.

Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R.

J Clin Microbiol. 2009 Jun;47(6):1640-4. doi: 10.1128/JCM.02135-08. Epub 2009 Apr 15.

5.

Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.

Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Siu LK, Lu PL.

J Microbiol Immunol Infect. 2012 Dec;45(6):435-41. doi: 10.1016/j.jmii.2012.05.004. Epub 2012 Jun 30.

6.

High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.

Wang JL, Lai CH, Lin HH, Chen WF, Shih YC, Hung CH.

Int J Antimicrob Agents. 2013 Nov;42(5):390-4. doi: 10.1016/j.ijantimicag.2013.07.010. Epub 2013 Aug 23.

PMID:
24041465
7.

Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.

Sancak B, Yagci S, Gür D, Gülay Z, Ogunc D, Söyletir G, Yalcin AN, Dündar DO, Topçu AW, Aksit F, Usluer G, Ozakin C, Akalin H, Hayran M, Korten V.

BMC Infect Dis. 2013 Dec 10;13:583. doi: 10.1186/1471-2334-13-583.

8.

Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.

van Hal SJ, Jones M, Gosbell IB, Paterson DL.

PLoS One. 2011;6(6):e21217. doi: 10.1371/journal.pone.0021217. Epub 2011 Jun 21.

9.

Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.

Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G.

J Infect Dis. 2009 Mar 1;199(5):619-24. doi: 10.1086/596629.

PMID:
19199552
10.

Characterization of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration.

Yamaguchi Y, Hanaki H, Yanagisawa C, Ikeda-Dantsuji Y, Hashimoto T, Yazaki H, Sugahara K, Yanagisawa T, Kawajiri H, Sato S, Ishizaki A, Tachihara-Sato R, Takahashi Y, Ono T, Kageyama Y, Kawaguchi T, Tamura A, Hagane K, Sunakawa K.

J Infect Chemother. 2009 Oct;15(5):274-8. doi: 10.1007/s10156-009-0703-y. Epub 2009 Oct 24.

PMID:
19856063
11.

Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.

Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, Mayall BC, Johnson PD, Grayson ML.

Antimicrob Agents Chemother. 2009 Aug;53(8):3447-52. doi: 10.1128/AAC.01365-08. Epub 2009 Jun 8.

12.

Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.

Sader HS, Jones RN, Rossi KL, Rybak MJ.

J Antimicrob Chemother. 2009 Nov;64(5):1024-8. doi: 10.1093/jac/dkp319. Epub 2009 Sep 10.

PMID:
19744978
13.
14.
15.

Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.

Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, Park SY, Moon SM, Chong YP, Kim SH, Lee SO, Choi SH, Jeong JY, Kim MN, Woo JH, Kim YS.

J Antimicrob Chemother. 2012 Aug;67(8):1843-9. doi: 10.1093/jac/dks131. Epub 2012 Apr 25.

PMID:
22535621
16.

Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.

Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM.

J Clin Microbiol. 2011 Jan;49(1):269-74. doi: 10.1128/JCM.00914-10. Epub 2010 Oct 20.

17.

Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections.

Butterfield JM, Tsuji BT, Brown J, Ashley ED, Hardy D, Brown K, Forrest A, Lodise TP.

Antimicrob Agents Chemother. 2011 Dec;55(12):5433-7. doi: 10.1128/AAC.00407-11. Epub 2011 Sep 19.

18.

Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.

Bae IG, Federspiel JJ, Miró JM, Woods CW, Park L, Rybak MJ, Rude TH, Bradley S, Bukovski S, de la Maria CG, Kanj SS, Korman TM, Marco F, Murdoch DR, Plesiat P, Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton KL, Corey GR, Fowler VG Jr; International Collaboration on Endocarditis-Microbiology Investigator.

J Infect Dis. 2009 Nov 1;200(9):1355-66. doi: 10.1086/606027.

19.

Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.

Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, Malik M, Mendes RE, Jones RN, McNutt LA, Lodise TP.

BMC Infect Dis. 2017 Aug 2;17(1):534. doi: 10.1186/s12879-017-2609-0.

20.

Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.

Hu HC, Kao KC, Chiu LC, Chang CH, Hung CY, Li LF, Liu TP, Lin LC, Chen NH, Huang CC, Yang CT, Lu JJ.

BMC Infect Dis. 2015 Oct 23;15:444. doi: 10.1186/s12879-015-1215-2.

Supplemental Content

Support Center